SYNLOGIC, INC. — Investor Relations & Filings

Synlogic, Inc. is a biopharmaceutical company that pioneers the development of Synthetic Biotics, a novel class of living medicines. By applying the principles of synthetic biology, the company engineers beneficial microbes to perform specific therapeutic functions directly within the gastrointestinal tract. These orally administered, non-systemically absorbed biotherapeutics are designed to treat serious metabolic and rare diseases by consuming toxic substances or producing therapeutic compounds. Synlogic's approach operates at the intersection of biology and engineering, aiming to program living cells to address the underlying drivers of disease in innovative ways.